BiotechTube

CE1226

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alpha1 Antitrypsin Deficiency

Conditions

Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema

Trial Timeline

Apr 15, 2026 → Sep 15, 2033

NCT ID
NCT07326592

About CE1226

CE1226 is a approved stage product being developed by CSL for Alpha1 Antitrypsin Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07326592. Target conditions include Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT07326592ApprovedRecruiting

Competing Products

6 competing products in Alpha1 Antitrypsin Deficiency

See all competitors
ProductCompanyStageHype Score
VX-864 + PlaceboVertex PharmaceuticalsPhase 2
51
Alpha1-proteinase inhibitorCSLApproved
84
Alpha-1 15% + Liquid Alpha1-Proteinase Inhibitor (Human)GrifolsPhase 1/2
38
Alpha-1 MPGrifolsPhase 1/2
38
Alpha-1 MPGrifolsPhase 1/2
38
ZF874 + PlaceboCentessa PharmaceuticalsPhase 1
28

Other Products from CSL

IgPro10Approved
84
four factor prothrombin complex concentrateApproved
84
Prothrombin complex concentrate (Human) + Fresh frozen plasma (FFP)Approved
84
IgPro10Approved
84
Blood coagulation Factor VIII and vWF, humanApproved
84